News
Former TI Pharma project moves into the clinic: first volunteers injected with promising malaria vaccine
The injection in three volunteers is the first official step in the human trial programme in the Leiden University Medical Center (LUMC) and the Radboudumc in Nijmegen. This trial investigates a promising malaria vaccine, Sanaria® PfSPZ-GA1 Vaccine, manufactured by biotechnology firm Sanaria.
The initial objective is to test weakened or attenuated parasites in the vaccine do not cause malaria in clinical trial volunteers. Development of the genetically attenuated parasite by the LUMC, Radboudumc and the Sanaria team was supported by TI Pharma (now Lygature). Although vaccines based on radiation attenuated malaria parasites have been studied in multiple clinical trials, this is the first clinical trial assessing an injectable genetically modified malaria vaccine.
More information can be found in the LUMC Press Release.